<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572597</url>
  </required_header>
  <id_info>
    <org_study_id>IRB100-26</org_study_id>
    <nct_id>NCT01572597</nct_id>
  </id_info>
  <brief_title>Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy</brief_title>
  <official_title>Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and
      amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole,
      clarithromycin, amoxicillin and metronidazole) for re-eradication for gastric Helicobacter
      pylori infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Antimicrobial resistance has decreased the eradication rates of common used
      triple therapy for Helicobacter pylori infection (less than 80%). Such treatment for patient
      previously with treatment failure, the retreatment eradication rate is less then 50%. Some
      studies showed the Helicobacter pylori form biofilm to prevent entry of antibiotics, and the
      N-acetylcystein is helpful to dissolve the biofilm.

      Objective: To determine the eradication rate of the common used triple therapy after adding
      N-acetylcystein for second line treatment for adults infected with Helicobacter pylori in
      Eastern Taiwan.

      Design: Randomized, open-label, prospective controlled trial.

      Patients: who are previously failed the primary treatment for eradication and still infected
      by Helicobacter pylori.

      Measurements: 13C-urea breath test, upper endoscopy, histologic evaluation, rapid urease
      test, bacterial culture, assessment of antibiotic resistance and CYP2C19 genotype of host.

      Intervention: patients with Helicobacter pylori eradication treatment failure are recruited
      and randomly assigned to receive one of the following therapeutic schemes: 1) study group:
      rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + N-acetylcystein 0.6g
      bid for 10 days; 2) control group: rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin
      0.5g bid + metronidazole 0.5g bid for 10 days. Repeat upper endoscopy for histologic
      evaluation, rapid urease test or 13C-urea breath test after 4 week of treatment to assess the
      treatment result. The influence on the hybrid therapies of antibiotic resistance of
      Helicobacter pylori and CYP2C19 genotype of host were determined.

      Expected results: The new second line treatment for eradication of Helicobacter pylori is
      effective, and to determine the relation of antibiotic resistance of Helicobacter pylori and
      CYP2C19 genotype of host to the treatment result.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Re-eradication rate</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>A negative post-treatment 13C-urea breath test result at more than 4 weeks after complete use of drug for treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of Participant's CYP2C19 genotype on re-eradication rate</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>Influence of Participant's CYP2C19 genotype (EM, IM or PM) on re-eradication rate of Helicobacter pylori</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bacterial Infection Due to Helicobacter Pylori (H. Pylori)</condition>
  <arm_group>
    <arm_group_label>Acetylcystein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-day triple therapy plus N-acetyl-cystein to remove the biofilm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10-day triple therapy plus metronidazole (concomitant therapy) as active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10RAC+acetylcystein</intervention_name>
    <description>10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d</description>
    <arm_group_label>Acetylcystein</arm_group_label>
    <other_name>Pariet</other_name>
    <other_name>Klaricid</other_name>
    <other_name>Hiconcil</other_name>
    <other_name>Fluimucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10RAC+metronidazole</intervention_name>
    <description>10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d</description>
    <arm_group_label>Metronidazole</arm_group_label>
    <other_name>Pariet</other_name>
    <other_name>Klaricid</other_name>
    <other_name>Hiconcil</other_name>
    <other_name>Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient after treatment for Helicobacter pylori eradication.

          -  Still clinically with evidence of gastric Helicobacter pylori infection.

        Exclusion Criteria:

          -  woman in breast feeding or pregnancy.

          -  allergy to drugs used in study.

          -  never treated for H. pylori.

          -  intolerance to fructose, lactose.

          -  patients with hematologic, brain or spinal disorders.

          -  patients under 20 years old.

          -  patients with malignancy or with decompensated function of vital organs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Cheh CHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Cheh CHEN, M.D.</last_name>
    <phone>+886-910-521003</phone>
    <email>MingCheh_chen@tzuchi.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Cheh CHEN, MD</last_name>
      <phone>+886-910-521003</phone>
      <email>MingCheh_chen@tzuchi.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chi-Tan HU, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Yi RAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan;8(1):36-41.e1. doi: 10.1016/j.cgh.2009.09.030. Epub 2009 Oct 3.</citation>
    <PMID>19804842</PMID>
  </reference>
  <reference>
    <citation>Cammarota G, Branca G, Ardito F, Sanguinetti M, Ianiro G, Cianci R, Torelli R, Masala G, Gasbarrini A, Fadda G, Landolfi R, Gasbarrini G. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010 Sep;8(9):817-820.e3. doi: 10.1016/j.cgh.2010.05.006. Epub 2010 May 31.</citation>
    <PMID>20478402</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Cheh Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>antibiotic resistance</keyword>
  <keyword>N-acetylcystein</keyword>
  <keyword>biofilm</keyword>
  <keyword>second-line eradication treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

